Cleaved HMWK Biomarker Assay for Autoimmune Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective diagnostics and monitoring for autoimmune diseases like rheumatoid arthritis, Crohn's disease, and ulcerative colitis, and there is a need for assessing treatment efficacy, as elevated levels of cleaved high molecular weight kininogen (HMWK) are not adequately addressed.
Innovation Solution
Measuring the levels of cleaved HMWK in biological samples using assays like ELISA or Western blotting, and administering plasma kallikrein inhibitors to diagnose, monitor, and treat these autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods are used for autoimmune diseases, then existing diagnostic protocols can be maintained, but diagnostic accuracy and monitoring capability are insufficient
Solution Approach 1:
The patent identifies and measures specific biomarker parameters (cleaved HMWK levels) that change in response to autoimmune disease activity. By monitoring these dynamic parameter changes rather than relying on static diagnostic criteria, the system achieves both improved diagnostic accuracy and continuous monitoring capability, resolving the contradiction between measurement precision and reliability.
2Ease of manufacture
If no specific biomarker is used, then diagnostic complexity is low, but treatment efficacy assessment is impossible
Solution Approach 1:
The patent extracts and focuses on a specific biomarker (cleaved HMWK) from the complex biological sample matrix. By isolating and measuring this single informative parameter rather than analyzing all possible markers, the system maintains diagnostic simplicity while gaining the ability to assess treatment efficacy, thus resolving the contradiction between ease of manufacture and information loss.
3Reliability
If plasma kallikrein inhibitors are administered, then disease progression is inhibited, but monitoring treatment response is challenging
Solution Approach 1:
The patent implements a feedback mechanism by measuring cleaved HMWK levels before and after treatment administration. The change in biomarker levels provides direct feedback on treatment response, allowing clinicians to assess whether the plasma kallikrein inhibitor is effectively inhibiting disease progression. This feedback loop resolves the contradiction between treatment effectiveness and response monitoring capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a reliable biomarker for diagnosing and monitoring autoimmune diseases and assessing treatment efficacy by measuring cleaved HMWK levels, offering a targeted approach with plasma kallikrein inhibitors for effective management.
Implementation Method 1
The level of cleaved HMWK is measured by an assay that involves a binding agent (e.g., an antibody) specific to cleaved HMWK
Implementation Method 2
The activation of pKal occurs via the contact system which has been demonstrated to be causative in the disease pathology associated with hereditary angioedema (HAE)
Data Source
AI summary
Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis. Crohn's disease, and ulcerative colitis.